Why Pheon Is Keeping Mum Over Target For Novel ADC

Intense competition in ADCs means Pheon is holding back details on its technology as it heads into Phase I studies after a $120m series B fundraising.

Antibody Drug Conjugate
• Source: Shutterstock

More from Business

More from Scrip